Kura Oncology has made significant strides in advancing its clinical programs, particularly with ziftomenib. The company recently announced that its pivotal Phase 2 KOMET-001 trial in ...

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines ...

骨髓是人体造血的“工厂”，而骨髓增生异常肿瘤（MDS）则是这座工厂的“生产线故障”——血细胞发育异常，导致贫血、感染甚至白血病风险升高。 过去，MDS诊断高度依赖骨髓涂片的形态学观察，但仅凭细胞形态差异（如“病态造血”），难以区分MDS与其他 ...

Acasunlimab是一种在研PD-L1/4-1BB双抗，它融合了Genmab公司专有的DuoBody技术平台和BioNTech公司专有的免疫调节抗体。 该研究表明 ...

1 Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China 2 Department of Pediatric Surgery, Jiangxi Provincial Children’s Medical Center, Jiangxi ...

In the era of precision medicine, radiation medicine is currently focused on the precise delivery of highly conformal radiation treatments. However, the tremendous developments in targeted therapy are ...